169 related articles for article (PubMed ID: 28864137)
1. Adjuvant Peptide Pulsed Dendritic Cell Vaccination in Addition to T Cell Adoptive Immunotherapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Ma CKK; Clancy L; Simms R; Burgess J; Deo S; Blyth E; Micklethwaite KP; Gottlieb DJ
Biol Blood Marrow Transplant; 2018 Jan; 24(1):71-77. PubMed ID: 28864137
[TBL] [Abstract][Full Text] [Related]
2. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
[TBL] [Abstract][Full Text] [Related]
3. Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells.
Van Craenenbroeck AH; Smits EL; Anguille S; Van de Velde A; Stein B; Braeckman T; Van Camp K; Nijs G; Ieven M; Goossens H; Berneman ZN; Van Tendeloo VF; Verpooten GA; Van Damme P; Cools N
Transplantation; 2015 Jan; 99(1):120-7. PubMed ID: 25050468
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation.
Micklethwaite K; Hansen A; Foster A; Snape E; Antonenas V; Sartor M; Shaw P; Bradstock K; Gottlieb D
Biol Blood Marrow Transplant; 2007 Jun; 13(6):707-14. PubMed ID: 17531781
[TBL] [Abstract][Full Text] [Related]
5. Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation.
Maffini E; Giaccone L; Festuccia M; Brunello L; Busca A; Bruno B
Expert Rev Hematol; 2016 Jun; 9(6):585-96. PubMed ID: 27043241
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation.
Micklethwaite KP; Clancy L; Sandher U; Hansen AM; Blyth E; Antonenas V; Sartor MM; Bradstock KF; Gottlieb DJ
Blood; 2008 Nov; 112(10):3974-81. PubMed ID: 18768783
[TBL] [Abstract][Full Text] [Related]
7. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
9. [Cytomegalovirus specific cytotoxic T lymphocytes for treatment of refractory cytomegalovirus infection in patients following allogeneic hematopoietic stem cell transplantation].
Xu Z; Huang X; Sun Y; Wang F; Yan C; Zhang X; Han W; Chen Y; Wang J; Chen H; Wang Y; Zhang Y; Liu K; Xu L
Zhonghua Nei Ke Za Zhi; 2015 Feb; 54(2):101-5. PubMed ID: 25907838
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy.
Cho SY; Lee DG; Kim HJ
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151230
[TBL] [Abstract][Full Text] [Related]
11. Protective immunity transferred by infusion of cytomegalovirus-specific CD8(+) T cells within donor grafts: its associations with cytomegalovirus reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation.
Luo XH; Huang XJ; Liu KY; Xu LP; Liu DH
Biol Blood Marrow Transplant; 2010 Jul; 16(7):994-1004. PubMed ID: 20167279
[TBL] [Abstract][Full Text] [Related]
12. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.
Borchers S; Luther S; Lips U; Hahn N; Kontsendorn J; Stadler M; Buchholz S; Diedrich H; Eder M; Koehl U; Ganser A; Mischak-Weissinger E
Transpl Infect Dis; 2011 Jun; 13(3):222-36. PubMed ID: 21585633
[TBL] [Abstract][Full Text] [Related]
13. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
14. T-cell therapy for cytomegalovirus infection.
Mui TS; Kapp M; Einsele H; Grigoleit GU
Curr Opin Organ Transplant; 2010 Dec; 15(6):744-50. PubMed ID: 20930639
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of adoptive T-cell therapy in treating cytomegalovirus infections post-haematopoietic stem cell transplantation: A systematic review and meta-analysis.
Taherian MR; Azarbar P; Barkhordar M; Toufani S; Aliabadi LS; Bahri T; Ahmadvand M; Yaghmaie M; Daneshvar A; Vaezi M
Rev Med Virol; 2024 Jul; 34(4):e2558. PubMed ID: 38878003
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection.
Locatelli F; Bertaina A; Bertaina V; Merli P
Expert Rev Hematol; 2016 Nov; 9(11):1093-1105. PubMed ID: 27690683
[TBL] [Abstract][Full Text] [Related]
17. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.
Peggs KS; Verfuerth S; Pizzey A; Khan N; Guiver M; Moss PA; Mackinnon S
Lancet; 2003 Oct; 362(9393):1375-7. PubMed ID: 14585640
[TBL] [Abstract][Full Text] [Related]
18. Adoptive therapy with cytomegalovirus-specific cytotoxic T lymphocytes for refractory cytomegalovirus DNAemia and disease after allogeneic haematopoietic stem cell transplantation.
Jiang Z; Fan Z; Zhang T; Lin R; Xu H; Xu N; Huang F; Chi P; Ou X; Wang Z; Liu H; Zhao K; Jiang L; Yu S; Sun J; Liu Q; Xuan L
Br J Haematol; 2024 Apr; 204(4):1393-1401. PubMed ID: 38168845
[TBL] [Abstract][Full Text] [Related]
19. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.
Lilleri D; Fornara C; Chiesa A; Caldera D; Alessandrino EP; Gerna G
Haematologica; 2008 Feb; 93(2):248-56. PubMed ID: 18245650
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy.
Peggs KS; Mackinnon S
Hum Immunol; 2004 May; 65(5):550-7. PubMed ID: 15172456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]